By Billy Candra 
A groundbreaking study conducted by researchers at Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden has fundamentally reshaped our understanding of how children’s immune systems combat cancer. Published in the esteemed scientific journal Cell, the investigation reveals critical age-dependent variations in immune responses to different cancer types, marking a significant departure from adult oncology paradigms. These profound differences between pediatric and adult immune systems hold immense potential for the development of novel, precisely tailored treatments, offering a beacon of hope for young patients facing the formidable challenge of cancer.
The activation and regulation of the immune system are paramount to its efficacy in fighting malignant diseases, yet this intricate process is demonstrably distinct in children compared to adults. As Professor Petter Brodin, a leading expert in pediatric immunology at the Department of Women’s and Children’s Health, Karolinska Institutet, and a pediatrician at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital, emphasizes, "If we’re to properly treat childhood cancer, we need to find out how the child’s immune system is activated and regulated in children with cancer and what factors affect their immune responses." This study represents a monumental leap in addressing that crucial knowledge gap, laying the groundwork for a new era of personalized medicine in pediatric oncology.
The Unique Landscape of Childhood Cancer
Childhood cancer, while relatively rare compared to adult malignancies, remains a leading cause of disease-related death among children and adolescents globally. Approximately 400,000 children are diagnosed with cancer each year worldwide, with around 300 new cases identified annually in Sweden alone. Unlike many adult cancers, which are often linked to lifestyle factors or environmental exposures, pediatric cancers typically arise from developmental cells, making their biology inherently distinct. They frequently present with fewer genetic mutations, exhibit different histological types—such as leukemias, brain tumors, neuroblastoma, and various sarcomas—and often grow at a more aggressive pace.
The current standard treatments for childhood cancer, including chemotherapy, radiation therapy, and surgery, have dramatically improved survival rates over the past few decades. However, these aggressive therapies can inflict significant and debilitating long-term side effects, ranging from cardiac and neurological complications to secondary cancers and impaired growth and development. This stark reality underscores an urgent need for more precise, less toxic, and highly effective treatment modalities that can improve both survival rates and the overall quality of life for pediatric cancer survivors. The study from Karolinska Institutet offers a pivotal step towards achieving this delicate balance.
Pioneering a New Dimension in Precision Medicine
The concept of precision medicine in oncology has revolutionized adult cancer care, moving away from a one-size-fits-all approach to treatments specifically designed for an individual’s tumor characteristics. Historically, this has predominantly focused on analyzing the genetic mutations within the tumor itself, identifying specific molecular alterations that can be targeted by advanced drugs. While immensely valuable, Professor Brodin points out a crucial missing piece: "Precision medicine in cancer has mostly focused on the tumour properties. By characterizing the immune system, we’re introducing an entirely new dimension that will be instrumental in shaping the future of childhood cancer therapy."
This novel approach acknowledges that the tumor exists within a complex biological environment, intrinsically linked to the host’s immune system. Understanding this interplay, particularly in the unique context of a developing child’s immune system, is critical for unlocking new therapeutic avenues. The study’s methodology was robust, involving a comprehensive analysis of 191 children, aged 0 to 18, who were diagnosed with various types of solid tumors at the Astrid Lindgren Children’s Hospital between 2018 and 2024. Researchers meticulously analyzed both tumor tissue and blood samples to ascertain the genetic mutations present in the tumors and, critically, to determine which genes were active or inactive within the child’s immune system. This dual-pronged investigation provided an unprecedented holistic view of the tumor microenvironment and the systemic immune response in pediatric cancer patients.
The Immune System’s Double-Edged Sword in Cancer
The immune system’s primary role is to identify and eliminate foreign invaders and abnormal cells, including nascent cancer cells—a process known as immune surveillance. Key players in this defense include T cells, particularly cytotoxic T lymphocytes (often referred to as killer T cells), and natural killer (NK) cells, which are programmed to detect and destroy compromised cells. However, cancer cells are notoriously adept at developing sophisticated mechanisms to evade or suppress this immune attack. They can hide their identity, release immunosuppressive molecules, or even co-opt immune cells to promote tumor growth.
Tumors are often categorized as "hot" or "cold" based on the degree of immune cell infiltration. "Hot" tumors are characterized by a robust presence of activated immune cells, signaling an ongoing immune response, albeit often an ineffective one due to immune evasion strategies. "Cold" tumors, conversely, have few infiltrating immune cells, indicating a lack of significant immune recognition or activation. The findings from the Karolinska Institutet study reveal a critical insight into pediatric cancers: "What we can see is that children’s tumours are generally less inflammatory and have fewer mutations," explains Professor Brodin. "This means that they likely appear less foreign to the immune system and that the immune system therefore doesn’t attack the tumours as forcefully." This inherent characteristic of pediatric tumors—being less inflammatory and bearing fewer mutations—suggests that they present a less recognizable target for the child’s immune system, leading to a weaker, less aggressive immune response.
Crucially, the study also highlighted significant individual variations among children. Even within the general trend of less inflammatory tumors, some patients exhibited distinct immune profiles, underscoring the absolute necessity of precision medicine tailored to each individual’s unique biological makeup. This finding reinforces the principle that a generalized approach to cancer treatment, even within pediatrics, is often insufficient.
The Immunotherapy Conundrum: Why Adult Successes Don’t Always Translate
The past decade has witnessed a revolution in adult oncology with the advent of immunotherapies, particularly checkpoint inhibitors. Drugs like pembrolizumab, nivolumab, and ipilimumab, which block immune checkpoints such as PD-1, PD-L1, and CTLA-4, have delivered remarkable and durable responses in various adult cancers, including melanoma, lung cancer, and kidney cancer. These therapies work by "releasing the brakes" on T cells, allowing them to mount a more vigorous attack against tumor cells.
However, the efficacy of checkpoint inhibitors in pediatric solid tumors has been markedly limited, leading to perplexing questions within the scientific community. The Karolinska Institutet study provides a compelling explanation for this disparity. As Professor Brodin elucidates, for checkpoint inhibitors to be effective, "This requires the immune cells to be activated against the tumour. We show that the child’s immune cells are often initially not activated against the tumour, which means that checkpoint inhibitors won’t work." In essence, if the immune system is not actively engaged in fighting the tumor in the first place—if the "engine isn’t running"—then releasing the "brakes" (via checkpoint inhibitors) will yield little to no therapeutic benefit.
This profound insight mandates a paradigm shift in the development of immunotherapies for children. Instead of therapies that merely unleash a pre-existing immune response, children likely require different types of immunotherapies that are specifically designed to trigger the immune cells to attack the tumor cells from scratch. This could involve novel approaches such as oncolytic viruses, which selectively infect and destroy cancer cells while also stimulating an immune response; cancer vaccines designed to educate the child’s immune system to recognize specific tumor antigens; or advanced adoptive cell therapies, which engineer a child’s own immune cells to target and eliminate cancer. The focus must shift from enhancing an existing response to initiating one where none effectively exists.
Tracking the Immune Response: A Real-Time Clinical Tool
Beyond revealing fundamental differences, the study also demonstrated a practical application for immediate clinical use. By tracking the immune response over time and during treatment in some of the participating children, researchers were able to measure dynamic changes in the population of killer T cells—the primary immune effector cells responsible for eliminating tumor cells. This capability offers a powerful new tool for clinicians.
"This is something that we could make clinical use of today to judge the therapeutic effect and adjust the treatment to every individual patient," Professor Brodin states. The ability to monitor the activity and numbers of killer T cells in real-time could provide invaluable feedback on how a child’s body is responding to therapy. This allows for a more agile and responsive approach to treatment, enabling clinicians to make informed decisions about whether to continue, modify, escalate, or switch therapies based on objective immunological markers, rather than solely relying on traditional imaging or clinical symptoms, which often lag behind the biological reality. The researchers are now planning to test this methodology on a larger scale, confident that it can serve as a highly useful complement to the genomic analyses of tumors that are already standard practice in routine care.
Broader Implications and the Future Horizon of Pediatric Oncology
The findings of this landmark study are poised to have far-reaching implications for pediatric oncology worldwide. By providing a foundational understanding of the unique immunological landscape in children with cancer, the research opens numerous avenues for future investigation and therapeutic innovation. It will undoubtedly stimulate the development of entirely new classes of immunotherapies specifically designed for the pediatric immune system, rather than merely adapting adult treatments.
This paradigm shift necessitates a greater emphasis on collaborative, multi-disciplinary research efforts involving pediatric oncologists, immunologists, geneticists, and pharmacologists. The study itself was conducted in close collaboration with the Astrid Lindgren Children’s Hospital paediatric oncology clinic at Karolinska University Hospital, underscoring the vital role of integrated clinical and translational research environments.
Furthermore, the research highlights the critical importance of continued and sustained funding for pediatric cancer research. This complex and resource-intensive work relies heavily on the support of organizations dedicated to fighting childhood diseases. The study was generously financed by a consortium of leading institutions, including the Swedish Cancer Society, the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, and Karolinska Institutet. Such collective investment is essential for translating groundbreaking scientific discoveries into tangible clinical benefits for children.
This study stands as a testament to the fact that children are not merely smaller versions of adults when it comes to disease biology and immune responses. Their developing immune systems present unique challenges and opportunities in the fight against cancer. By meticulously unraveling these distinctions, Professor Petter Brodin, alongside Linda Ljungblad (oncology resident and researcher at Karolinska Institutet), and their dedicated team have laid a robust scientific foundation for a new generation of pediatric cancer therapies. This promises not only to improve survival rates but also to significantly enhance the long-term health and quality of life for countless children diagnosed with cancer, marking a pivotal moment in the ongoing battle against this devastating disease.
(Disclosure: Petter Brodin and two of the other authors are co-founders of Cytodelics AB. Petter Brodin is a member of the Kancera AB executive board and a scientific advisor to Pixelgen Technologies AB, Sention Health AB, Helaina Inc, Scailyte AG and Oxford Immune Algorithmics.)
